Expanded Hospital Network Healthy Sales of the Company’s Core Products 1H 2023’s Operating Revenue Surged 90% to RMB104 million Ocumension…
Expanded Hospital Network Healthy Sales of the Company’s Core Products 1H 2023’s Operating Revenue Surged 90% to RMB104 million Ocumension…
Youshiying (OT-401), Company’s Core Product, Commercialized ahead of Schedule Speed up the Launch of New Products Ocumension Therapeutics (Ocumension or…